Cannabidiol for the treatment of chronic pain in the temporomandibular joint

Cannabidiol in patients with chronic pain due to Temporomandibular dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-4yp5qgz

Enrollment

Registered

2026-05-12

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular disorders Cannabidiol

Interventions

This study is a randomized, controlled, two-arm, triple-blind clinical trial. Randomization was performed by another researcher who did not participate in the clinical experiment. Experimental group:

Eligibility

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years; good general health; temporomandibular dysfunction associated with chronic pain according to the evaluation criteria of this study

Exclusion criteria

Exclusion criteria: Allergy and/or hypersensitivity to the components of cannabidiol or placebo; exposed skin lesions in the application area; cannabis addiction; use of fixed and/or removable prostheses; autoimmune diseases or disorders associated with generalized muscle tension

Design outcomes

Primary

Measure	Time frame
It was expected that 2.5% transdermal Cannabidiol would result in a significant reduction in temporomandibular joint pain, as measured by the visual analog scale for pain, while the placebo would not significantly change the level of pain in the temporomandibular joint region, as measured by the visual analog scale for pain, within a period of 14 days;No difference was found in the reduction of pain in the temporomandibular joint region, as measured by the visual analog scale for pain, between the cannabidiol and placebo groups over a 14-day period	—

Measure

Time frame

It was expected that 2.5% transdermal Cannabidiol would result in a significant reduction in temporomandibular joint pain, as measured by the visual analog scale for pain, while the placebo would not significantly change the level of pain in the temporomandibular joint region, as measured by the visual analog scale for pain, within a period of 14 days;No difference was found in the reduction of pain in the temporomandibular joint region, as measured by the visual analog scale for pain, between the cannabidiol and placebo groups over a 14-day period

—

Secondary

Measure	Time frame
It was expected that 2.5% transdermal cannabidiol would result in the maintenance of pain reduction in the temporomandibular joint region, as measured by the visual analog pain scale, after 30 days of treatment, while the placebo would not change the level of pain in the temporomandibular joint region, as measured by the visual analog pain scale, after 30 days of treatment;The placebo group showed a significantly greater reduction in pain intensity than the group treated with cannabidiol after 30 days of treatment	—

Measure

Time frame

It was expected that 2.5% transdermal cannabidiol would result in the maintenance of pain reduction in the temporomandibular joint region, as measured by the visual analog pain scale, after 30 days of treatment, while the placebo would not change the level of pain in the temporomandibular joint region, as measured by the visual analog pain scale, after 30 days of treatment;The placebo group showed a significantly greater reduction in pain intensity than the group treated with cannabidiol after 30 days of treatment

—

Countries

Contacts

Public ContactGláucia Colli

Universidade de Passo Fundo

glau_colli@hotmail.com+55(54)999587471

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Jun 11, 2026